^
Association details:
| Biomarker: | TCF3-PBX1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
Published date:
09/02/2016
Excerpt:
Both relapse samples of the TCF3-PBX1 BCP-ALL index patient were highly sensitive to idelalisib (CAL-101, GS-1101).
DOI:
10.1038/leu.2016.202
